Table 4. Logistic regression comparing biomakers and biomarker ratios by cardiac stage among T-cruzi infected (Tc+) individuals. Cutoffs were determined by ROC analysis.

				AB vs CD
	N(%)			Univariate		Multivariate*
	Stage A	Stage B	Stage CD	OR (95% CI)	p-value	OR (95% CI)	p-value
Biomarker (pg/ml)
BNP
<103.64 pg/ml	29 (61.7)	24 (60.0)	34 (40.0)	1.0		1.0
≥103.64 pg/ml	18 (38.3)	16 (40.0)	51 (60.0)	2.29 (1.28–4.09)	0.005	2.29 (1.26–4.16)	0.004
NTproBNP
<287.83 pg/ml	40 (85.1)	30 (75.0)	23 (27.1)	1.0		1.0
≥287.83 pg/ml	7 (14.9)	10 (25.0)	62 (72.9)	7.16 (3.77–13.59)	<0.001	7.14 (3.68–13.83)	<0.001
Troponin I
<174.97 pg/ml	32 (68.1)	23 (57.5)	33 (38.8)	1.0		1.0
≥174.97 pg/ml	15 (31.9)	17 (42.5)	52 (61.2)	2.60 (1.44–4.68)	0.001	2.48 (1.36–4.51)	0.003
MMP-2
<93311 pg/ml	36 (75.0)	25 (61.0)	33 (39.8)	1.0		1.0
≥93311 pg/ml	12 (25.0)	16 (39.0)	50 (60.2)	2.87 (1.58–5.19)	0.001	2.70 (1.47–4.98)	0.001
TIMP-1
<154120 pg/ml	24 (54.5)	23 (62.2)	24 (33.8)	1.0		1.0
≥154120 pg/ml	20 (45.5)	14 (37.8)	47 (66.2)	2.56 (1.34–4.88)	0.004	2.38 (1.23–4.59)	0.010
TIMP-2
<88677 pg/ml	22 (0.5)	27 (73.0)	26 (36.6)	1.0		1.0
≥88677 pg/ml	22 (0.5)	10 (27.0)	45 (63.4)	3.64 (1.89–7.01)	<0.001	3.57 (1.83–6.97)	<0.001
Biomarker Ratio
MMP-2/MMP-9
<0.45 pg/ml	26 (54.2)	15 (36.6)	32 (38.6)	1.0		1.0
≥0.45 pg/ml	22 (45.8)	26 (63.4)	51 (61.4)	1.88 (1.05–3.38)	0.033	2.05 (1.10–3.83)	0.021
MMP-2/TGFB1
<3.37 pg/ml	36 (0.75)	24 (64.9)	32 (39.0)	1.0		1.0
≥3.37 pg/ml	12 (0.25)	13 (35.1)	50 (61.0)	2.91 (1.59–5.30)	<0.001	3.02 (1.62–5.63)	<0.001

*Multivariate analyses adjusted for age, sex, and presence of comorbidities (hypertension, diabetes, and coronary artery disease).